Partial
Partially Aligned
Patient Risk:
Medium
Summary
Mechanism and description claims align with the provided label sections. However, multiple efficacy/trial claims were marked as not supported due to missing Section 14 text, which is a material alignment failure for a label-consistency audit. Required safety sections (contraindications, boxed warning, dosing/monitoring, special populations) were not evaluated.
Category Scores
Accurate Statements
Kerendia contains the active ingredient finerenone.
11 DESCRIPTION
Kerendia is a non-steroidal mineralocorticoid receptor (MR) antagonist.
11 DESCRIPTION; 12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action)
Kerendia blocks the harmful effects of excessive mineralocorticoid receptor stimulation.
12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action)
Unsupported Statements
Kerendia can contribute to slowing chronic kidney disease (CKD) progression in patients with type 2 diabetes.
Only partially supported by the provided label excerpt; the label wording provided is risk reduction for sustained eGFR decline/end-stage kidney disease rather than explicit phrasing of 'slowing CKD progression.'
Kerendia can reduce cardiovascular complications in patients with type 2 diabetes.
Only partially supported by the provided label excerpt; the label wording provided is risk reduction for cardiovascular death and hospitalization for heart failure rather than explicit phrasing of 'cardiovascular complications.'
Clinical trials have demonstrated that Kerendia can significantly reduce the risk of kidney disease progression in patients with type 2 diabetes and CKD.
No Section 14 clinical-study text was provided in the prompt; therefore support cannot be verified from the supplied label content. (The audit determination labeling this as 'absent from the label' is also not verifiable from the provided prompt.)
Clinical trials have demonstrated that Kerendia can significantly reduce the risk of cardiovascular events in patients with type 2 diabetes and CKD.
No Section 14 clinical-study text was provided in the prompt; therefore support cannot be verified from the supplied label content. (The audit determination labeling this as 'absent from the label' is also not verifiable from the provided prompt.)
In the FIDELIO-DKD trial, Kerendia reduced the composite outcome of kidney disease progression or cardiovascular death.
No Section 14 clinical-study text was provided in the prompt; therefore support cannot be verified from the supplied label content.
In the FIGARO-DKD trial, Kerendia reported a significant reduction in cardiovascular events.
No Section 14 clinical-study text was provided in the prompt; therefore support cannot be verified from the supplied label content.
Contradictions
Important Omissions
No evaluation of contraindications, boxed warning, dosing/administration details, monitoring/hyperkalemia safety, drug interactions, adverse reactions, or special population details (pregnancy, pediatrics).
Importance:
High
For efficacy/trial claims, the prompt did not include Section 14 text; the response (as assessed) did not provide or tie claims to the specific labeled endpoint language available in Section 1.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
While the mechanism/description and broad risk-reduction indication statements are consistent with the provided excerpts, the audit improperly treated Section 14 efficacy support as absent despite it being a likely label basis (not verifiable from provided text). Additionally, key safety-critical label areas (contraindications, boxed warning, dosing/monitoring) were not evaluated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several effectiveness/trial outcome claims rely on Section 14 information that was not provided in the prompt, and the alignment determinations were not defensible from available label excerpts. Safety-critical label sections were not assessed.
Suggested Improvement
Restrict efficacy/trial claims to the exact Section 1 labeled risk-reduction endpoints provided, or supply and cite Section 14 text for any FIDELIO-DKD/FIGARO-DKD outcome assertions. Expand the audit to include contraindications, boxed warning, dosing/administration and monitoring/hyperkalemia safety, drug interactions, adverse reactions, and special populations (pregnancy and pediatrics) from the label.